| |
Tuesday, November 19, 2024 | 2pm ET / 11am PT Join us to learn about the latest strategies and solutions for storing, accessing and using data more effectively. Discover how the scientific community can now open the door to an array of choices for rapidly performing complex analyses on massive data sets, building and training generative AI models, and protecting and securing critical data stores. Register now. 
|
|
| By Nick Paul Taylor A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial. |
|
|
|
By Zoey Becker The company opted not to renew its membership for 2025 following an annual review of its trade group associations, a spokesperson said. |
By Nick Paul Taylor The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol Myers Squibb. |
By Fraiser Kansteiner Thermo Fisher is cutting a total of 160 jobs across three different viral vector facilities in Cambridge, Lexington and Plainville, according to a government filing in Massachusetts. In tandem with the staff reduction, Thermo Fisher also plans to shutter its facility in Lexington. |
|
Wednesday, November 20, 2024 | 11am ET / 8am PT Join us for a deep dive into electronic Clinical Outcome Assessment (eCOA) systems. We'll explore the latest trends and strategies tailored for increasingly complex clinical trial environments. Learn about the current and future state of eCOA technology, potential areas for enhancement, ways to leverage effectively, and more. Register now. 
|
|
By Conor Hale During quarterly earnings calls this week across the medtech industry, a recurring question has been on investors’ minds. |
By Angus Liu After a series of acquisitions and an activist investor's accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit, Reuters reports. |
By Conor Hale The genetics testing company plans to seek out new homes for its in-house pipeline of DNA-informed immuno-oncology antibodies. |
By Nick Paul Taylor Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin pens to $1 per device in low- and middle-income countries (LMICs). |
By Darren Incorvaia The in vivo cell therapy seed that Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. The biotechs teamed up to develop a method to engineer immune cells called macrophages to target solid tumors. |
By Zoey Becker The company will tack on two more multicustomer suites and 200 new jobs at its bioconjugation manufacturing facility in Visp, Switzerland. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
|
|---|
|
|
|
Wednesday, November 20, 2024 | 11am ET / 8am PT Join us to discover how to overcome challenges, and learn about practical solutions for scalability and safety in cell therapy manufacturing. Don't miss out, register today. 
|
|
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Selecting a 3PL with a proven track record of delivering high-quality services is critical to a successful pharma supply chain. Here's how. Sponsored by: BioCare |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Direct-To-Patient Cash Solutions for Pharma Manufacturers – learn how to leverage cash models strategically to mitigate access challenges and overcome the hurdles faced in today’s retail pharmacy environment. Sponsored by: KnippeRx |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
Survey Explore the latest trends in compliance monitoring to help your team embrace proactive strategies in key areas of risk management. Stay ahead of the ever-evolving landscape and new policies to enhance your compliance program. Sponsored by: IQVIA |
Research Read this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
.png)
